What is new in the FDA approval?

The FDA approved an extended maintenance dosing regimen of once every eight weeks, offering added flexibility.

How does this affect Eli Lilly?

It expands Eli Lilly's dermatology portfolio beyond obesity and diabetes, diversifying revenue streams.

FDA Approves Extended Dosing Regimen for Eli Lilly's Ebglyss

Q: Is Ebglyss covered by insurance?

Yes, Ebglyss has broad coverage from national pharmacy benefit managers.

The FDA approved an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises.

June 10, 2026

2 min read

Source: Simply Wall St.

The U.S. Food and Drug Administration (FDA) has approved an extended once-every-eight-weeks maintenance dosing regimen for Ebglyss (lebrikizumab-lbkz) in moderate-to-severe atopic dermatitis. The decision expands Eli Lilly's (NYSE:LLY) dermatology footprint beyond its obesity and diabetes drug franchises.

The Product

Ebglyss is a monoclonal antibody targeting IL-13, a key driver of inflammation in atopic dermatitis. The new regimen offers patients dosing flexibility with injections every eight weeks instead of more frequent schedules.

Pricing and Availability

Eli Lilly has not disclosed pricing details yet, but Ebglyss already has broad coverage from national pharmacy benefit managers, facilitating patient access.

Competition

Ebglyss competes with drugs like Dupixent (Regeneron/Sanofi) and Adbry (LEO Pharma). The less frequent dosing may provide a competitive edge.

Potential Impact on the Company

This approval diversifies Eli Lilly's revenue beyond obesity and diabetes drugs like Mounjaro and Zepbound. Ebglyss is expected to contribute to dermatology segment growth, though sales depend on commercial adoption.

Frequently Asked Questions

Ebglyss (lebrikizumab-lbkz) is a monoclonal antibody targeting IL-13 for moderate-to-severe atopic dermatitis.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.